213 related articles for article (PubMed ID: 21616914)
21. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
Tervaert JW; Stegeman CA
Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
[TBL] [Abstract][Full Text] [Related]
22. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
23. Necrotizing vasculitis--a 2009 update.
Sharaf PH; Yazici Y
Bull NYU Hosp Jt Dis; 2009; 67(3):303-5. PubMed ID: 19852754
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors.
Stassen PM; Derks RP; Kallenberg CG; Stegeman CA
Rheumatology (Oxford); 2008 Apr; 47(4):530-4. PubMed ID: 18356178
[TBL] [Abstract][Full Text] [Related]
25. Review article: Progress of treatment in ANCA-associated vasculitis.
Jayne D
Nephrology (Carlton); 2009 Feb; 14(1):42-8. PubMed ID: 19335843
[TBL] [Abstract][Full Text] [Related]
26. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.
Robson J; Doll H; Suppiah R; Flossmann O; Harper L; Höglund P; Jayne D; Mahr A; Westman K; Luqmani R
Ann Rheum Dis; 2015 Jan; 74(1):177-84. PubMed ID: 24243925
[TBL] [Abstract][Full Text] [Related]
27. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
Knight A; Askling J; Granath F; Sparen P; Ekbom A
Ann Rheum Dis; 2004 Oct; 63(10):1307-11. PubMed ID: 15130900
[TBL] [Abstract][Full Text] [Related]
28. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
29. The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey.
Pamuk ÖN; Dönmez S; Calayır GB; Pamuk GE
Clin Rheumatol; 2016 Aug; 35(8):2063-2071. PubMed ID: 26992904
[TBL] [Abstract][Full Text] [Related]
30. Cancer incidence rates among Lawrence Livermore National Laboratory (LLNL) employees: 1974-1997.
Whorton MD; Moore DN; Seward JP; Noonan KA; Mendelsohn ML
Am J Ind Med; 2004 Jan; 45(1):24-33. PubMed ID: 14691966
[TBL] [Abstract][Full Text] [Related]
31. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis.
Little MA; Nightingale P; Verburgh CA; Hauser T; De Groot K; Savage C; Jayne D; Harper L;
Ann Rheum Dis; 2010 Jun; 69(6):1036-43. PubMed ID: 19574233
[TBL] [Abstract][Full Text] [Related]
32. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
33. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases.
Asten P; Barrett J; Symmons D
J Rheumatol; 1999 Aug; 26(8):1705-14. PubMed ID: 10451066
[TBL] [Abstract][Full Text] [Related]
34. Malignancy is increased in patients with antineutrophil cytoplasmic antibody-associated vasculitis in China.
Han XY; Li ZY; Zhao MH; Little MA; Chen M
Arthritis Res Ther; 2024 May; 26(1):113. PubMed ID: 38822382
[TBL] [Abstract][Full Text] [Related]
35. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
36. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
[TBL] [Abstract][Full Text] [Related]
37. No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis.
Le Bouc R; Zéphir H; Majed B; Vérier A; Marcel M; Vermersch P
Mult Scler; 2012 Jan; 18(1):55-63. PubMed ID: 21844065
[TBL] [Abstract][Full Text] [Related]
38. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy in women diagnosed with antineutrophil cytoplasmic antibody-associated vasculitis: outcome for the mother and the child.
Tuin J; Sanders JS; de Joode AA; Stegeman CA
Arthritis Care Res (Hoboken); 2012 Apr; 64(4):539-45. PubMed ID: 22162518
[TBL] [Abstract][Full Text] [Related]
40. Clinical and pathological characteristics and outcomes of Chinese patients with primary anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with immune complex deposition in kidney.
Yu F; Chen M; Wang SX; Zou WZ; Zhao MH; Wang HY
Nephrology (Carlton); 2007 Feb; 12(1):74-80. PubMed ID: 17295665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
